Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.41 |
| ▸ | BCR | P11274 | 7/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4665807 | 0.96 | HTR6 (0.44) | ABL1BCRKITHTR6GSK3B | |
| Formic Acid SCHEMBL4666206 | 0.95 | ABL1 (0.41) | ABL1BCRKITHTR6GSK3B | |
| Formic Acid SCHEMBL4666096 | 0.93 | PAX8 (0.43) | KITHTR6HRH3GSK3BACP1 | |
| Formic Acid SCHEMBL4665737 | 0.92 | LMNA (0.42) | ABL1BCRKITHTR6GSK3B | |
| Formic Acid SCHEMBL4667472 | 0.89 | PAX8 (0.44) | KITHTR6TP53GSK3BALDH1A1 | |
| Formic Acid SCHEMBL4666146 | 0.88 | HTR6 (0.38) | KITHTR6GSK3BALDH1A1MAPT | |
| Formic Acid SCHEMBL4665624 | 0.88 | HTR6 (0.46) | ABL1BCRHTR6GSK3BALDH1A1 | |
| Formic Acid SCHEMBL4666082 | 0.87 | HRH3 (0.53) | ABL1BCRKITHRH3MAPT | |
| Formic Acid SCHEMBL4666026 | 0.87 | GSK3B (0.42) | ABL1BCRGSK3BALDH1A1LMNA | |
| Formic Acid SCHEMBL4667521 | 0.87 | HTR6 (0.46) | ABL1BCRHTR6GSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885KIT 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.